From the Department of Neurology, Severance Hospital (H.K.N.), Yonsei University College of Medicine (J.K.), Seoul; Department of Bio-convergence Engineering (J.-H.S., J.-K.S.), and School of Biomedical Engineering (J.-K.S.), Korea University, Seoul; and Department of Neurology, Sungkyunkwan University School of Medicine (H.J.K., S.W.S., D.L.N.), and Neuroscience Center (H.J.K., S.W.S., D.L.N), Samsung Medical Center, Seoul, Republic of Korea.
Neurology. 2018 May 15;90(20):e1751-e1758. doi: 10.1212/WNL.0000000000005524. Epub 2018 Apr 20.
To investigate differential atrophy patterns based on the presence of cortical superficial siderosis (cSS) and the role of cSS in predicting amyloid positivity in memory clinic patients fulfilling the diagnostic criteria for probable cerebral amyloid angiopathy (CAA).
We retrospectively collected data from 44 cognitively impaired patients with probable CAA who underwent 3-dimensional, T1-weighted MRIs (cSS+, n = 27; cSS-, n = 17). Amyloid-positive patients with Alzheimer disease (AD) (n = 56) and amyloid-negative cognitively normal participants (n = 34) were recruited as controls. Among the patients with CAA who underwent amyloid-PET scans (75.0%), we investigated whether amyloid-negative cases were unevenly distributed based on cSS presentation. genotypes, Mini-Mental State Examination scores, and cortical atrophy pattern along with hippocampal volume were compared across groups.
Ten patients with probable CAA presented amyloid negativity and all of them belonged to the cSS- group (58.8%). Compared to the cSS- group, the cSS+ group presented higher ε4 frequency, worse memory dysfunction, and lower hippocampal volume. Compared with cognitively normal participants, the cSS+ group exhibited atrophy in the precuneus, posterior cingulate, parietotemporal, superior frontal, and medial temporal areas, a pattern similar to AD-specific atrophy. The cSS- group exhibited atrophy in the parietotemporal, superior frontal, and precentral regions.
Our findings imply that the current version of the Boston criteria may not be sufficient enough to remove non-CAA cases from a cognitively impaired population, especially in the absence of cSS. Patients with probable CAA presenting cSS appear to reflect a CAA phenotype that shares pathologic hallmarks with AD, providing insight into the CAA-to-AD continuum.
研究基于皮质浅表铁沉积(cSS)存在的差异萎缩模式,以及 cSS 在预测满足可能的脑淀粉样血管病(CAA)诊断标准的记忆门诊患者中淀粉样蛋白阳性的作用。
我们回顾性收集了 44 名认知障碍且可能患有 CAA 的患者的数据,这些患者均接受了 3 维 T1 加权 MRI(cSS+,n=27;cSS-,n=17)。招募了 56 名患有阿尔茨海默病(AD)的淀粉样蛋白阳性患者(AD 组)和 34 名认知正常的淀粉样蛋白阴性参与者作为对照组。在接受淀粉样蛋白-PET 扫描的 CAA 患者中(75.0%),我们研究了 cSS 表现是否导致淀粉样蛋白阴性病例的分布不均匀。比较了各组之间的 基因型、简易精神状态检查评分以及皮质萎缩模式和海马体积。
10 名可能患有 CAA 的患者表现为淀粉样蛋白阴性,且均属于 cSS-组(58.8%)。与 cSS-组相比,cSS+组的 ε4 频率更高,记忆功能障碍更严重,海马体积更小。与认知正常参与者相比,cSS+组在前扣带回、后扣带回、顶颞叶、额上回和内侧颞叶出现萎缩,表现为类似 AD 特异性萎缩的模式。cSS-组则在顶颞叶、额上回和中央前回出现萎缩。
我们的研究结果表明,当前版本的波士顿标准可能不足以将非 CAA 病例从认知障碍人群中排除,特别是在没有 cSS 的情况下。表现出 cSS 的可能患有 CAA 的患者似乎反映了一种与 AD 具有共同病理特征的 CAA 表型,为 CAA-AD 连续体提供了深入的见解。